Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial
Yonsei Medical Journal
;
: 1354-1360, 2016.
Article
in English
| WPRIM
| ID: wpr-81713
ABSTRACT
PURPOSE:
A phase I clinical trial was conducted to evaluate the immunogenicity and safety of newly developed egg-cultivated trivalent inactivated split influenza vaccine (TIV) in Korea. MATERIALS ANDMETHODS:
The TIV was administered to 43 healthy male adults. Subjects with high pre-existing titers were excluded in a screening step. Immune response was measured by a hemagglutination inhibition (HI) assay.RESULTS:
The seroprotection rates against A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2009 were 74.42% [95% confidence interval (CI) 61.38–87.46], 72.09% (95% CI 58.69–85.50), and 86.05% (95% CI 75.69–96.40), respectively. Calculated seroconversion rates were 74.42% (95% CI 61.38–87.46), 74.42% (95% CI 61.38–87.46), and 79.07% (95% CI 66.91–91.23), respectively. There were 25 episodes of solicited local adverse events in 21 subjects (47.73%), 21 episodes of solicited general adverse events in 16 subjects (36.36%) and 5 episodes of unsolicited adverse events in 5 subjects (11.36%). All adverse events were grade 1 or 2 and disappeared within three days.CONCLUSION:
The immunogenicity and safety of TIV established in this phase I trial are sufficient to plan a larger scale clinical trial.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Influenza Vaccines
/
Mass Screening
/
Influenza, Human
/
Seroconversion
/
Hemagglutination
/
Korea
Type of study:
Screening study
Limits:
Adult
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
English
Journal:
Yonsei Medical Journal
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS